Adeno-Associated Viral Vectors Industry Outlook 2025-2029: Market Set to Cross $6.08 Billion Milestone

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Adeno-Associated Viral Vectors Market Size By 2025?
The market for adeno-associated viral vectors has experienced swift progress in the last few years. The market, which is set to climb from $2.69 billion in 2024 to $3.17 billion in 2025, boasts a compound annual growth rate (CAGR) of 17.9%. Factors contributing to growth during the historical period include advances in vaccine development, financial growth and investment, collaborations between academia and industry, the expansion of clinical trials, and increased levels of public consciousness and advocacy.

How Big Is the Adeno-Associated Viral Vectors Market Size Expected to Grow by 2029?
In the forthcoming years, the market for adeno-associated viral vectors is predicted to experience a swift ascension. It is projected to mount up to $6.08 billion by 2029, following a compound annual growth rate (CAGR) of 17.6%. The market expansion during the forecast period can be credited to several factors including broadening therapeutic uses, a growing number of genetic disorders and neurological conditions, regulatory endorsements and backing, and production cost cutbacks. The key trends to look out for during the forecast period include progress in gene therapy, technological breakthroughs, scalability in manufacturing processes, partnerships and funding, and innovative technological strides.

View the full report here:
https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report

Which Key Market Drivers Powering Adeno-Associated Viral Vectors Market Expansion and Growth?
The rise in the occurrence of genetic diseases is anticipated to boost the adeno-associated viral vectors market's expansion in the future. Genetic disorders arise from anomalies in a person's DNA, leading to physical or developmental irregularities. Advanced diagnostic methods, increased awareness, higher reproductive age, coupled with environmental influences and genetic drift are contributing to the surge in genetic disorders. Adeno-associated viral vectors serve a pivotal role in gene therapy for genetic disorders, by transmitting corrective genes into cells to conceivably mitigate conditions such as muscular dystrophy or cystic fibrosis. For instance, in February 2023, the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations strictly for international public health, estimated that congenital diseases led to approximately 240,000 infants' deaths worldwide within 28 days of their birth each year. Furthermore, congenital diseases also result in the death of an extra 170,000 children aged between one month and five years. Hence, the escalating incidence of genetic disorders is stimulating the adeno-associated viral vectors market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15969&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Adeno-Associated Viral Vectors Market?
Several leading players in the adeno-associated viral vectors market are striving to obtain a competitive advantage by providing readily accessible replication-capsid plasmid. These Rep/Cap plasmids, often used in AAV vector production for gene therapy, are easily accessible from various commercial vendors who cater to molecular biology research requirements. For instance, in January 2024, the US-based pharmaceutical firm, Charles River Laboratories International Inc., launched an off-the-shelf range of replication-capsid plasmids, significantly simplifying AAV-based gene therapy projects. This product range expansion complements their existing lentiviral packaging and AAV Helper plasmid offerings, thereby reducing manufacturing efforts by up to 66%. These plasmids, ready for use, undergo batch production with careful documentation in compliance with CMC guidelines and come with Certification of Analysis (COA) to aid IND and Clinical Trial Application (CTA) submissions.

What Are the Emerging Segments in the Adeno-Associated Viral Vectors Market?
The adeno-associated viral vectors market covered in this report is segmented -

1) By Type Of Therapy: Gene Augmentation, Immunotherapy, Other Type Of Therapies
2) By Type Of Gene Delivery Method Used: Ex Vivo, In Vivo
3) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Areas
4) By Scale Of Operation: Preclinical, Clinical, Commercial
5) By Application Area: Gene Therapy, Cell Therapy, Vaccines

Subsegments:
1) By Gene Augmentation: Inherited Genetic Disorders, Muscular Dystrophy, Cystic Fibrosis, Hemophilia
2) By Immunotherapy: Cancer Immunotherapy, Viral Infections Immunotherapy, Autoimmune Diseases Immunotherapy
3) By Other Types Of Therapies: Gene Editing, RNA Therapy, Antiviral Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15969&type=smp

Who Are the Global Leaders in the Adeno-Associated Viral Vectors Market?
Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc, MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics

Which are the Top Profitable Regional Markets for the Adeno-Associated Viral Vectors Industry?
North America was the largest region in the adeno-associated viral vectors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15969

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.